Circulating Tumour Cells Indicate the Presence of Residual Disease Post-Castration in Prostate Cancer Patient-Derived Xenograft Models.
castrate-resistant prostate cancer
circulating tumour cell
epithelial mesenchymal plasticity
kallikrein related peptidase 3
metastasis
patient-derived xenograft
prostate specific antigen
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
01
2022
accepted:
09
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Castrate-resistant prostate cancer (CRPC) is the lethal form of prostate cancer. Epithelial mesenchymal plasticity (EMP) has been associated with disease progression to CRPC, and prostate cancer therapies targeting the androgen signalling axis, including androgen deprivation therapy (ADT), promote EMP. We explored effects of castration on EMP in the tumours and circulating tumour cells (CTCs) of patient-derived xenograft (PDX)-bearing castrated mice using human-specific RT-qPCR assays and immunocytochemistry. Expression of prostate epithelial cell marker KLK3 was below detection in most tumours from castrated mice (62%, 23/37 mice), consistent with its known up-regulation by androgens. Endpoint tumour size after castration varied significantly in a PDX model-specific pattern; while most tumours were castration-sensitive (BM18, LuCaP70), the majority of LuCaP105 tumours continued to grow following castration. By contrast, LuCaP96 PDX showed a mixed response to castration. CTCs were detected in 33% of LuCaP105, 43% of BM18, 47% of LuCaP70, and 54% of LuCaP96 castrated mice using
Identifiants
pubmed: 35493092
doi: 10.3389/fcell.2022.858013
pii: 858013
pmc: PMC9043137
doi:
Types de publication
Journal Article
Langues
eng
Pagination
858013Informations de copyright
Copyright © 2022 Hassan, Blick, Wood, Thompson and Williams.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Invest Surg. 2001 Sep-Oct;14(5):251-2
pubmed: 11700917
Clin Cancer Res. 2021 Apr 1;27(7):1967-1973
pubmed: 33500355
Science. 2013 Feb 1;339(6119):580-4
pubmed: 23372014
Cells. 2019 Jan 20;8(1):
pubmed: 30669516
Carcinogenesis. 2008 Dec;29(12):2267-78
pubmed: 18791199
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Curr Oncol Rep. 2017 May;19(5):32
pubmed: 28361223
Cell Commun Signal. 2015 May 15;13:26
pubmed: 25975820
Cells Tissues Organs. 2022;211(2):110-133
pubmed: 33902034
FASEB J. 2010 Mar;24(3):769-77
pubmed: 19901020
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Pathol Int. 2016 Nov;66(11):601-608
pubmed: 27510923
J Pathol Clin Res. 2019 Oct;5(4):272-286
pubmed: 31464093
Front Oncol. 2014 Dec 23;4:370
pubmed: 25566507
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38
pubmed: 30131604
Endocr Relat Cancer. 2015 Jun;22(3):R165-82
pubmed: 25934687
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Nat Rev Clin Oncol. 2014 Jul;11(7):401-12
pubmed: 24821215
Endocrinol Metab Clin North Am. 2011 Sep;40(3):577-90, ix
pubmed: 21889722
Sci Rep. 2016 Feb 03;6:18074
pubmed: 26838463
Front Oncol. 2015 Jul 20;5:155
pubmed: 26258068
Prostate. 2005 Sep 15;65(1):35-43
pubmed: 15800936
Prostate Cancer. 2012;2012:327253
pubmed: 22530130
Cell Commun Signal. 2020 Jul 11;18(1):110
pubmed: 32650779
Clin Exp Metastasis. 2019 Aug;36(4):393-409
pubmed: 31190270
Cancers (Basel). 2020 Jun 19;12(6):
pubmed: 32575608
Cancers (Basel). 2017 Jul 29;9(8):
pubmed: 28758926
Mol Endocrinol. 2013 Feb;27(2):280-95
pubmed: 23250485
Nat Commun. 2020 Jan 20;11(1):384
pubmed: 31959826
Clin Chem. 2019 Jan;65(1):87-99
pubmed: 30602476
Prostate. 2009 May 15;69(7):787-98
pubmed: 19189306
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Cancer Res. 2017 Jan 1;77(1):74-85
pubmed: 27793843
Medicine (Baltimore). 2019 May;98(19):e15608
pubmed: 31083254
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):151-157
pubmed: 29997040
Cancers (Basel). 2021 Jun 01;13(11):
pubmed: 34206049
Cells. 2019 Jul 03;8(7):
pubmed: 31277346
Rev Assoc Med Bras (1992). 2017 Aug;63(8):722-725
pubmed: 28977112
Cancer Cell. 2012 Jan 17;21(1):66-81
pubmed: 22264789
Clin Genitourin Cancer. 2015 Aug;13(4):295-301
pubmed: 26007708
Cancers (Basel). 2019 Sep 20;11(10):
pubmed: 31547070
Nat Commun. 2018 Nov 26;9(1):4972
pubmed: 30478344
EBioMedicine. 2019 Aug;46:133-149
pubmed: 31375425
Nat Rev Cancer. 2019 Dec;19(12):716-732
pubmed: 31666716
Cancer Res. 2012 Jan 15;72(2):527-36
pubmed: 22108827
Genes Dev. 2017 Sep 15;31(18):1827-1840
pubmed: 29051388
Br J Cancer. 2020 Dec;123(12):1767-1774
pubmed: 32901137
EBioMedicine. 2019 Aug;46:4-5
pubmed: 31399383
Cancer Metastasis Rev. 2012 Dec;31(3-4):673-87
pubmed: 22733306
Transl Oncol. 2021 Apr;14(4):101026
pubmed: 33535154
Cancer Treat Rev. 2016 May;46:42-50
pubmed: 27107266
Sci Rep. 2017 Nov 9;7(1):15140
pubmed: 29123322
Oncotarget. 2015 Jan 20;6(2):1202-16
pubmed: 25483103
Nature. 2018 Apr;556(7702):442-444
pubmed: 29686367
Adv Exp Med Biol. 2018;1095:1-14
pubmed: 30229546
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):229-238
pubmed: 29981816
Cell Rep. 2016 Dec 6;17(10):2632-2647
pubmed: 27926867
Hepatology. 2018 Sep;68(3):807-810
pubmed: 29331068
BJU Int. 2019 Aug;124(2):258-267
pubmed: 30536520
Asian J Androl. 2014 Mar-Apr;16(2):248-55
pubmed: 24407178
Cancer Res. 2015 Jul 1;75(13):2749-59
pubmed: 25948589
J Mol Med (Berl). 2017 Feb;95(2):133-142
pubmed: 28013389
Breast Cancer Res Treat. 2017 Jan;161(1):83-94
pubmed: 27771841
Eur Urol. 2009 Mar;55(3):533-42
pubmed: 19013008
Pharmacol Ther. 2013 Dec;140(3):223-38
pubmed: 23859952
JAMA. 2005 Jul 13;294(2):238-44
pubmed: 16014598
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):
pubmed: 29311132
J Steroid Biochem Mol Biol. 2017 Feb;166:84-90
pubmed: 27189666
Front Oncol. 2012 Oct 11;2:131
pubmed: 23087897
Nature. 2018 Apr;556(7702):463-468
pubmed: 29670281
FASEB J. 2008 May;22(5):1512-20
pubmed: 18055862
Mol Cancer. 2014 Feb 24;13:37
pubmed: 24565133
Prostate. 2018 Dec;78(16):1262-1282
pubmed: 30073676
Oncogene. 2010 Sep 2;29(35):4947-58
pubmed: 20562913
J Biol Chem. 2003 Dec 12;278(50):50402-11
pubmed: 14523021
Oncogene. 2019 Feb;38(7):913-934
pubmed: 30194451
Proc Natl Acad Sci U S A. 2021 May 11;118(19):
pubmed: 33941680
Oncology. 2016;91(1):48-54
pubmed: 27256106
Urology. 2000 Mar;55(3):323-7
pubmed: 10699601
Br J Cancer. 2008 Feb 26;98(4):756-65
pubmed: 18268494
PLoS One. 2015 May 28;10(5):e0126522
pubmed: 26020648
Br J Cancer. 2012 May 22;106(11):1790-7
pubmed: 22538972
Cancer Discov. 2018 Mar;8(3):288-303
pubmed: 29301747
Neoplasia. 2003 Jul-Aug;5(4):347-61
pubmed: 14511406
Cancer Res. 2021 Dec 1;81(23):5800-5802
pubmed: 34853039
Eur Urol Focus. 2019 Mar;5(2):147-154
pubmed: 30772358
Transl Androl Urol. 2016 Dec;5(6):961-963
pubmed: 28078231
Curr Oncol Rep. 2016 Jan;18(1):3
pubmed: 26700506
Br J Cancer. 2016 Mar 15;114(6):659-68
pubmed: 26954717
Eur Urol. 2012 Mar;61(3):549-59
pubmed: 22099611
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Trends Cancer. 2019 Jul;5(7):440-455
pubmed: 31311658
Minerva Urol Nefrol. 2018 Feb;70(1):22-41
pubmed: 28707844
F1000Res. 2018 Sep 18;7:
pubmed: 30271576
Br J Cancer. 2011 Oct 25;105(9):1338-41
pubmed: 21970878
Steroids. 2019 Dec;152:108497
pubmed: 31521707
Br J Radiol. 2014 Mar;87(1035):20130676
pubmed: 24588669
Int J Cancer. 2019 Mar 15;144(6):1421-1431
pubmed: 30070688
Prostate. 2017 May;77(6):654-671
pubmed: 28156002